Status:
COMPLETED
Noninvasive Hemodynamics Assessment of Preterms With Successful Medical Closure of PDA
Lead Sponsor:
Tanta University
Conditions:
Patent Ductus Arteriosus in Preterm Infants
Eligibility:
All Genders
24-7 years
Brief Summary
The aim of our study was to use Electrical Cardiometry EC to monitor hemodynamic alternations during pharmacological closure of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm ...
Detailed Description
PDA in the first three days of life is a normal physiologic remnant in healthy term neonates. Conversely, a PDA in preterm neonates causes significant clinical sequelae as a result from left to right ...
Eligibility Criteria
Inclusion
- All preterm newborns who were admitted throughout the duration of the research.
Exclusion
- Newborn with congenital heart diseases.
- Newborn with acquired heart diseases (viral myocarditis)
- Newborn with dysrhythmias
- Newborn with symptomatic cardiac dysfunction secondary to extra cardiac diseases
- Newborn with significant pulmonary hypertension or systemic hypertension
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2024
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT06606015
Start Date
October 1 2023
End Date
April 1 2024
Last Update
September 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Tanta University
Tanta, Egypt, 31527